USP25 aggravates liver cancer development and impairs chemosensitivity by limiting LATS1 activation - PubMed
6 hours ago
- #Deubiquitinase
- #Chemotherapy Resistance
- #Hepatocellular Carcinoma
- USP25 is overexpressed in hepatocellular carcinoma (HCC) and promotes tumor growth by deubiquitinating LATS1.
- USP25 removes K63-linked ubiquitin at K688 of LATS1, disrupting LATS1-MOB1 complex formation and enhancing YAP/TAZ activity.
- Depletion of USP25 suppresses HCC cell and tumor growth, indicating its role in cancer progression.
- A cell-penetrating peptide targeting the USP25-LATS1 interaction increases p-YAP and improves chemotherapy sensitivity in models.
- Targeting USP25 provides a potential therapeutic strategy for HCC by restoring LATS1 activation and chemosensitivity.